AzTrials
AzTrials

Arthroplasty ComplicationsPhase 4NCT05707234

Virtual Reality Hypnosis in Total Knee Arthroplasty Under Spinal Anesthesia

A Phase 4 study testing VRH and Midazolam sedation in people with Arthroplasty Complications and Knee Osteoarthritis, run by University of Liege at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. Read more about this study

Who is it for?
Ages 18 to 99 years
What is being tested?
VRH and Midazolam sedation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteBelgium
Study dates
15 Feb 2023to 3 Aug 2023
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients >18 yo and scheduled for elective knee arthroplasty under spinal anesthesia

Who cannot join

  • Low auditory and/or visual acuity that precludes the use of the device.
  • ASA status > 3
  • Head or face wounds precluding use of the device.
  • Schizophrenia or dissociative disorder.
  • Pregnancy.
  • Chronic renal insufficiency or severe hepatic insufficiency.
Show all 12Show fewer
  • Non-proficiency in French (Research language).
  • Phobia of deep water.
  • Chronic pain and/or chronic analgesics consumption.
  • Medication affecting the autonomic nervous system.
  • Revision surgery.
  • Dizziness.

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • CHU de Liège

    Liège, 4000

Other trials in Belgium

About this study

Official title: Can we Avoid Intravenous Sedation in Patients Undergoing Knee Surgery Under Spinal Anesthesia? A Prospective Randomized Controlled Study Comparing Virtual Reality Hypnosis to Standard of Care

For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. the intravenous administration of additional anesthetic agents such as propofol or midazolam. However, pharmacological sedation has considerable undesirable side effects. Hence, risks of intraprocedural adverse events including respiratory depression, hemodynamic perturbations, or paradoxical effects such as hostility, aggression, and psychomotor agitation, are increased. The goal of this prospective, single-center, randomized controlled clinical trial is to systematically evaluate the impact of implementing a protocol of virtual reality hypnosis in patients undergoing total knee arthroplasty under spinal anesthesia.

Read the detailed description

For many years, total knee arthroplasty (TKA) has been a common and effective procedure to treat chronic refractory joint pain. With a worldwide aging population, as well as a rising rate of obesity and related osteoarthritis, the utilization of TKA has considerably expanded over time, and this increase is expected to continue. Accordingly, healthcare systems are exploring various strategies to address this growing demand, while ensuring efficiency, cost-effectiveness and safety. Among these approaches, and based on several reports comparing the risks and benefits of general and regional anesthesia, a first attempt has been made to switch from performing TKAs under general to spinal anesthesia. Although efforts must be pursued, as general anesthesia remains the main tendency for TKA, results regarding spinal anesthesia are extremely encouraging. As such, spinal anesthesia has been associated with a decreased rate of complications, including wound infection, blood transfusions or mortality, and with reduced length of surgery and hospital stay.

Yet, while spinal anesthesia prevents procedural pain and ensures immobility of the operative territory, the patient is still awake, conscious of all the noises in the operating room, and can have a high level of intraoperative anxiety. Currently, the standard of care to manage procedural anxiety is pharmacological sedation; i.e. the intravenous administration of additional anesthetic agents such as propofol or midazolam. However, pharmacological sedation has considerable undesirable side effects. Hence, risks of intraprocedural adverse events including respiratory depression, hemodynamic perturbations, or paradoxical effects such as hostility, aggression, and psychomotor agitation, are increased. Moreover, it might lead to longer procedure duration or time to discharge, slower recovery, and postoperative delirium or cognitive dysfunction. In addition to these challenges, it becomes clear that procedural sedation directly impacts consumption of drugs such as opioids, triggering the highlighted risk of addiction.

In this context, new international guidelines for risk mitigation in pharmacological sedation have emerged. Both American and European anesthesia societies recommend particular caution in the use of sedative drugs, especially with benzodiazepines and in patients with obesity or obstructive sleep apnea, which are highly comorbid with knee osteoarthritis. However, only providing less, or even no sedatives at all, is not a valuable solution, as it would negatively impact patient comfort and satisfaction and negatively affect clinical workflow. Therefore, alternative, non-pharmacological interventions that would be able to reduce drug requirements and associated risks while ensuring a similar patient experience are being actively sought.

Among those approaches, there is currently a growing interest towards clinical hypnosis, a one-to-one delivered technique inducing "A state of consciousness involving focused attention and reduced peripheral awareness characterized by an enhanced capacity for response to suggestion". The hypnotic state involves the capacities of absorption (tendency to be fully involved in a mental experience), dissociation (a mental separation from the environment), and suggestibility (tendency to comply with hypnotic suggestions). When combined during surgery with conscious IV sedation and local or regional anesthesia, forming the so-called hypnosedation, clinical hypnosis is associated with improved perioperative safety and comfort as well as better clinical outcomes. More precisely, the use of clinical hypnosis during medical procedures has been shown to reduce pain, emotional distress and anxiety while preserving consciousness, spontaneous breathing, reflexes as well as hemodynamic and metabolic changes, to decrease the time spent in the operating room, and to have a beneficial impact on immediate recovery, characterized by reduced fatigue and postoperative nausea and vomiting (PONV). Furthermore, this technique allows to significantly reduce the administrated doses of IV sedation and the associated costs. Yet, several obstacles limit the use of hypnosedation as a standard of care in the operating/ procedure room: the need for continuous patient-side presence of trained professionals in the room (and the cost related to the mobilization of these professionals), the small number of cases per day one healthcare provider can handle, patient's language proficiency, as well as the heterogeneity of the responses to the hypnotic suggestions of patients themselves.

To overcome those limitations, Oncomfort has created Digital Sedation™ sessions, classified as Software as a Medical Device (SaMD), allowing to deliver clinical hypnosis - together with additional integrative therapeutic approaches - through virtual reality, a technique called Virtual Reality Hypnosis (VRH). Virtual reality (VR) is "a computer-generated simulation of a lifelike environment that can be interacted with in a seemingly real or physical way by a person, by means of responsive hardware such as a visor with screen or gloves with sensors. In the medical field, VR has been used as a non-pharmacological mean to alleviate pain, anxiety, and general discomfort during uncomfortable procedures. VR is thought to work by distracting patients from uncomfortable procedures: by giving the illusion of really going into the artificial world, VR is able to capture patient's attention away from the real environment. Accordingly, VR could strengthen the level of absorption and dissociation induced by clinical hypnosis, especially in low hypnotizable persons. Hence, VRH technology allows to deliver clinical hypnosis - and its related benefits- to a considerably greater number of patients. This automated way of delivering hypnosis responds to most of the limitations of the use of clinical hypnosis mentioned supra (e.g. availability of trained staff, language barrier,…).

To date, the Oncomfort's Digital Sedation™ is used in more than 100 hospitals, and more than 80 000 patients have already beneficiated from this type of VRH in daily clinical practice (e.g. interventional radiology, oncology, surgery,…). In line with its intended use, first studies have demonstrated that Digital Sedation™ reduces both experimental and clinical pain, as well as procedural anxiety. In addition, preliminary results indicate that it might replace midazolam during endoscopic urologic surgery, avoiding the respiratory side effects associated with pharmacological sedation. Over the last year, at the CHU of Liège, Digital Sedation™ has been offered to patients during orthopedic surgeries, demonstrating the feasibility of using VRH during TKAs performed under spinal anesthesia. While results seem to be positive in terms of performance of the procedure and patient satisfaction, the potential beneficial impact of this solution has not been systematically addressed yet. The goal of the present study is to objectify those effects, and in particular, to determine whether VRH can replace - at least in part- the intraoperative administration of midazolam, allowing to avoid its associated side effects while ensuring a similar patient's comfort.

Being tested
VRH, Midazolam sedation
Medical subject headings
Osteoarthritis, Knee, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VRHDevice

    The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).

  • Midazolam sedationDrug

    During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.

Study groups in NCT05707234
Study groupRoleWhat they receive
Control GroupActive comparatorDuring the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached. Patients randomized to the control group will undergo perioperative anesthesia according to the current standards of care, without the addition of the VR headset or headphones.
Receives: Drug: Midazolam sedation
VRH GroupExperimentalThey will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. During the whole procedure, an anesthesiologist will perform the usual cares, including closely monitoring, and will administrate intravenous sedation (midazolam) when necessary (see sedation protocol in the previous section).
Receives: Device: VRH; Drug: Midazolam sedation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Midazolam milligrams

    Sedation: Intravenous milligrams of midazolam administered during first 120 minutes of surgery to achieve a RASS (Richmond Agitation-Sedation Scale) of -2 or -3.

    Measured: 2 hours

Secondary outcomes (12)
  1. Intensity of postoperative pain

    Pain (NRS 0-10)

    Measured: 1 hour, 24 hours, 48 hours after surgery and one week later

  2. Anxiety

    Anxiety (Numeric Rating Scale 0-10)

    Measured: 1 hour, 24 hours, 48 hours after surgery and one week later

  3. Anxiety

    Anxiety on State-Trait Anxiety Inventory scale (STAI-6)

    Measured: 1 hour, 24 hours, 48 hours after surgery and one week later

  4. Comfort

    Comfort during and after surgery (NRS 0-10)

    Measured: 1 hour, 24 hours, 48 hours after surgery and one week later

  5. Fatigue

    Fatigue (NRS 0-10)

    Measured: 1 hour, 24 hours, 48 hours after surgery and one week later

  6. Patient satisfaction

    Patient satisfaction (global experience) Likert 1-5

    Measured: 5 minutes after surgery

  7. Time perception

    Patient's time perception (estimated duration of the surgery, i.e. duration between incision and suture)

    Measured: 5 minutes after surgery

  8. Dissociation

    Dissociation (NRS 0-10)

    Measured: 5 minutes after surgery

  9. Anesthesiologist satisfaction

    Anesthesiologist satisfaction (Likert 1-5)

    Measured: 5 minutes after surgery

  10. Surgeon satisfaction

    Surgeon satisfaction (Likert 1-5)

    Measured: 5 minutes after surgery

  11. Nurse satisfaction

    Nurse satisfaction (Likert 1-5)

    Measured: 5 minutes after surgery

  12. QoR-15F

    Score on the quality of recovery, using the QoR-15F

    Measured: 1 hour, 24 hours, 48 hours after surgery and one week later

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jan 2023
  2. Study start15 Feb 2023
  3. Primary completion3 Aug 2023
  4. Study completion3 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
prospective, single-center, randomized controlled clinical trial
Masking
None (open label)
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05707234
Sponsor's protocol ID
VRH.TKA
Status last verified
Mar 2024
First submitted
4 Jan 2023
Last updated
6 Mar 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Carella M, Beck F, Quoilin C, Azongmo MM, Loheac A, Bonhomme VL, Vanhaudenhuyse A. Effect of virtual reality hypnosis on intraoperative sedation needs and functional recovery in knee arthroplasty: a prospective randomized clinical trial. Reg Anesth Pain Med. 2025 May 6;50(5):383-389. doi: 10.1136/rapm-2023-105261.

    PubMed 38413184

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing VRH and Midazolam sedation in people with Arthroplasty Complications and Knee Osteoarthritis, run by University of Liege at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Midazolam milligrams (time frame: 2 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05707234, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in